Hepatitis B Virus Infection Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Hepatitis B Virus Infection Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hepatitis B Virus Infection Pipeline Report
- DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
- The leading companies working in the Hepatitis B Virus Infection Market include Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
- Promising Hepatitis B Virus Infection Pipeline Therapies in the various stages of development include BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.
- November 2023: Hoffmann- La Roche announced a study of Phase 1 clinical trials for RO7565020. This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics following single and/or multiple doses of RO7565020 in healthy participants and/or virologically suppressed participants with chronic hepatitis B (CHB).
- November 2023: GlaxoSmithKline announced a study of Phase 2 clinical trials for GSK3228836. This study is a Phase IIa, multi-center open label exploratory study of the therapeutic mechanism of GSK3228836 in participants with hepatitis B virus e-antigen (HBeAg)-negative CHB on stable nucleos(t)ide therapy using repeat fine needle aspirations of the liver for intrahepatic immunophenotyping. It will investigate the virologic and immunologic correlates of hepatitis B virus surface antigen (HBsAg) loss observed in participants when treated for 12 weeks with 300 milligrams (mg) GSK3228836. Repeat fine needle aspirates of the liver will be performed to enable analysis of liver-resident immune cells to investigate any immunomodulatory properties of GSK3228836 and to study the biology of underlying treatment-associated liver flares. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately 20 participants will be enrolled in the study.
- October 2023: Janssen Research & Development LLC announced a study of Phase 2 clinical trials for JNJ-73763989 and Entecavir (ETV). The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment. A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection.
Request a sample and discover the recent advances in Hepatitis B Virus Infection Treatment Drugs @ Hepatitis B Virus Infection Pipeline Report
In the Hepatitis B Virus Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hepatitis B Virus Infection Overview
Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids. Oral-fecal transmission is possible but considerably rare.
Find out more about Hepatitis B Virus Infection Therapeutics Assessment @ Hepatitis B Virus Infection Preclinical and Discovery Stage Products
Hepatitis B Virus Infection Emerging Drugs Profile
- Bepirovirsen: GSK
- VIR 2218: Vir Biotechnology
- AB 729: Arbutus Biopharma
- AHB-137: Ausper Biopharma
Hepatitis B Virus Infection Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the Hepatitis B Virus Infection. The Hepatitis B Virus Infection companies which have their Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. phase III include, GSK.
DelveInsight’s Hepatitis B Virus Infection pipeline report covers around 90+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Hepatitis B Virus Infection Pipeline Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging Hepatitis B Virus Infection Pipeline Therapies @ Hepatitis B Virus Infection Clinical Trials Assessment
Scope of the Hepatitis B Virus Infection Pipeline Report
- Coverage- Global
- Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
- Hepatitis B Virus Infection Pipeline Therapies- BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.
Dive deep into rich insights for new drugs for Hepatitis B Virus Infection Treatment, Visit @ Hepatitis B Virus Infection Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Hepatitis B Virus Infection: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Bepirovirsen: GSK
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- VIR 2218: Vir Biotechnology
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AHB-137: Ausper Biopharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Hepatitis B Virus Infection Key Companies
- Hepatitis B Virus Infection Key Products
- Hepatitis B Virus Infection- Unmet Needs
- Hepatitis B Virus Infection- Market Drivers and Barriers
- Hepatitis B Virus Infection- Future Perspectives and Conclusion
- Hepatitis B Virus Infection Analyst Views
- Hepatitis B Virus Infection Key Companies
- Appendix
For further information on the Hepatitis B Virus Infection Pipeline therapeutics, reach out to Hepatitis B Virus Infection Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-market
){kind=link}